Cardiovascular Risk Assessment and Summary of Guidelines for the Management of Hypertension

[1]  B. Egan,et al.  US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. , 2010, JAMA.

[2]  G. Bakris,et al.  The kidney, hypertension, and remaining challenges. , 2009, The Medical clinics of North America.

[3]  G. Bakris,et al.  Hypertension and Kidney Disease: A Marriage That Should Be Prevented , 2009 .

[4]  G. Bakris,et al.  The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. , 2009, Kidney international.

[5]  G. Bakris,et al.  The Message for World Kidney Day 2009 , 2009, American Journal of Nephrology.

[6]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[7]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[8]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[9]  W. Gibler,et al.  Obesity and age of first non-ST-segment elevation myocardial infarction. , 2008, Journal of the American College of Cardiology.

[10]  G. Bakris,et al.  ASH Position Paper: Treatment of Hypertension in Patients With Diabetes—An Update , 2008, Journal of clinical hypertension.

[11]  Tal Geva,et al.  Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. , 2008, Journal of the American College of Cardiology.

[12]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[13]  B Neal,et al.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials , 2008, BMJ : British Medical Journal.

[14]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[15]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[16]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[17]  Frank B. Hu,et al.  Abdominal Obesity and the Risk of All-Cause, Cardiovascular, and Cancer Mortality: Sixteen Years of Follow-Up in US Women , 2008, Circulation.

[18]  J. Said.  Book Review AIDS-Associated Viral Oncogenesis (Cancer Treatment and Research. Vol. 133.) Edited by Craig Meyers. 270 pp., illustrated. New York, Springer, 2007. $149. 978-0-387-46804-4 , 2008 .

[19]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[20]  J. Filipovský,et al.  Diastolic Blood Pressure and Mortality in the Elderly With Cardiovascular Disease , 2007, Hypertension.

[21]  D. Goff,et al.  Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.

[22]  Keith C. Norris,et al.  Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). , 2007, Archives of internal medicine.

[23]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[24]  P. Greenland,et al.  Predictive Utility of Pulse Pressure and Other Blood Pressure Measures for Cardiovascular Outcomes , 2007, Hypertension.

[25]  G. Bakris,et al.  Antihypertensive agents, insulin sensitivity, and new-onset diabetes , 2007, Current diabetes reports.

[26]  G. Bakris,et al.  Erratum: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome (Diabetes Care (2006) 29 (2592-2597)) , 2007 .

[27]  G. Bakris.  Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome , 2007, Diabetes Care.

[28]  W. Elliott,et al.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2007, The Lancet.

[29]  M. Hack,et al.  Decrease in frequency of cerebral palsy in preterm infants , 2007, The Lancet.

[30]  A. Yamashina,et al.  Arterial stiffness and progression to hypertension in Japanese male subjects with high normal blood pressure , 2007, Journal of hypertension.

[31]  C. Lau,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004 , 2007, Hypertension.

[32]  T. Heise,et al.  Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients , 2006, Journal of hypertension.

[33]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[34]  Ralph B D'Agostino,et al.  Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age , 2006, Circulation.

[35]  L. Ruilope,et al.  Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study , 2006, Journal of hypertension.

[36]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[37]  L. Lindholm,et al.  Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.

[38]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[39]  J. Rouleau,et al.  Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. , 2005, Journal of the American Society of Nephrology : JASN.

[40]  D. E. Mathis,et al.  Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2005, Archives of internal medicine.

[41]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[42]  R. Hirschberg.  Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis. , 2004, Journal of the American Society of Nephrology : JASN.

[43]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[44]  Robert M Califf,et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.

[45]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[46]  P. Whelton,et al.  Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia , 2004, Journal of Human Hypertension.

[47]  J. Howell.  Book Review Flesh in the Age of Reason By Roy Porter. 574 pp. New York, Norton, 2004. $29.95. 0-393-05075-0 , 2004 .

[48]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[49]  N. Poulter,et al.  Hypertension management and control among English adults aged 65 years and older in 2000 and 2001 , 2004, Journal of hypertension.

[50]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[51]  B. Lévy.  Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin–Angiotensin System , 2003, Circulation.

[52]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[53]  P. Serruys,et al.  Late-Late Occlusion After Intracoronary Brachytherapy , 2003 .

[54]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[55]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[56]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[57]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[58]  Majid Ezzati,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[59]  R. D'Agostino,et al.  Risk stratification of obesity as a coronary risk factor. , 2002, The American journal of cardiology.

[60]  Ralph B D'Agostino,et al.  Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. , 2002, Archives of internal medicine.

[61]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[62]  W. Kannel.  Cardiovascular hazards of components of blood pressure. , 2002, Journal of hypertension.

[63]  B. Davis,et al.  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. , 2001, Controlled clinical trials.

[64]  D. Levy,et al.  Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease , 2001 .

[65]  A. Dyer,et al.  Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. , 2001, Archives of internal medicine.

[66]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[67]  Martin G. Larson,et al.  Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?: The Framingham Heart Study , 2001, Circulation.

[68]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[69]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[70]  Aminah Khan and Sami M. Shimi.  Gastro-oesophageal reflux disease , 2000, The Lancet.

[71]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[72]  P. Jousilahti,et al.  Excess mortality associated with increased pulse pressure among middle‐aged men and women is explained by high systolic blood pressure , 2000, Journal of hypertension.

[73]  D. Levy,et al.  Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. , 1999, Kidney international.

[74]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[75]  S. Poirier.  Performing Alzheimer's disease , 1999, The Lancet.

[76]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[77]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[78]  T. Perneger,et al.  Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments , 1998, BMJ.

[79]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[80]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[81]  P. Geltman.  Rwanda: physician complicity and rebuilding the medical community , 1997, The Lancet.

[82]  S. Hillier,et al.  Escherichia coli bacteriuria and contraceptive method. , 1991, JAMA.

[83]  L. Kuller,et al.  Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. , 1988, Circulation.

[84]  L. Monnier,et al.  Influence of Indigestible Fibers on Glucose Tolerance , 1978, Diabetes Care.

[85]  G. Mancia,et al.  New-onset diabetes and antihypertensive drugs. , 2006, Journal of Hypertension.

[86]  Alan C. Wilson,et al.  Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. , 2005, The American journal of cardiology.

[87]  D. Nutt,et al.  Discontinuation of Vioxx. Authors' reply , 2005 .

[88]  Deeb N Salem,et al.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. , 2003, Journal of the American College of Cardiology.

[89]  Leonard H. Epstein,et al.  Overweight, obesity, and health risk. , 2000, Archives of internal medicine.

[90]  W. Kannel,et al.  Risk stratification in hypertension: new insights from the Framingham Study. , 2000, American journal of hypertension.